CIBISATAMAB

UNII:	ZAM5J1ATF2
Formula:
Preferred Substance Name:	CIBISATAMAB

2101242-53-7
ANTI-CEA/CD3 BISPECIFIC ANTIBODY RO6958688
CEA CD3 TCB
CIBISATAMAB [INN]
CIBISATAMAB [USAN]
CIBISATAMAB [WHO-DD]
HUMANIZED IMMUNOGLOBULIN G1 (IGG1) T-CELL BISPECIFIC (TCB) ANTIBODY TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) AND CD3 EPSILON CHAIN (CD3E) ON T-CELLS
IMMUNOGLOBULIN G1, HUMANIZED BISPECIFIC TRIVALENT, ANTI-(HUMAN CARCINOEMBRYONIC ANTIGEN/HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) BIVALENT .GAMMA.-CHAIN, DISULFIDE WITH ANTI-(HUMAN CARCINOEMBRYONIC ANTIGEN) .KAPPA.-CHAIN, ANTI-(HUMAN CARCINOEMBRYONIC ANTIGEN) MONOVALENT .GAMMA.-CHAIN AND ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) .KAPPA.-CHAIN
RG7802
RO6958688
RO-6958688

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CIBISATAMAB

Synonyms and Mappings

Resources